logo-loader
viewBiocept Inc

Biocept bolsters its intellectual property arsenal with three new patents

The patents cover its antibody and microchannel technology and the detection of cancer cells, which collectively is used to capture cells of interest in a biopsy

Biocept Inc -
In particular, the technology aims to capture circulating tumor cells in patients with cancer

Biocept Inc (NASDAQ:BIOC), a liquid biopsy provider, has been awarded three new patents, the company announced Thursday, adding to its extensive intellectual property portfolio. 

The patents — one US, one Canadian and one European — cover Biocept’s antibody and microchannel technology and the detection of cancer cells, which collectively is used to capture cells of interest in a biopsy. 

In particular, the technology aims to capture circulating tumor cells (CTCs) in patients with cancer.

READ: Biocept shares rise after reporting revenue boost in 2Q

Specifically, the US patent covers the microchannel technology used to aid the capture of cells of interest, the Canadian patent covers the binding partners and methods used in the capture itself and the European patent covers a method of detecting cells using fluorescent complexes.

"Collectively, the granting of these additional patents further broadens Biocept's US and international footprint for capturing and analyzing any biological target of interest," the group's Chief Scientific Officer Lyle Arnold said in a statement. 

All told, Biocept is armed with an intellectual property portfolio of 36 patents around the world.

The company's share price fell 4.6% Tuesday to $1.04.

—Updated to include stock quote—

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Biocept Inc

Price: 0.528 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $12.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Biocept making great strides with its Switch-Blocker technology

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive that a peer-review journal named PLOS ONE has published validation results showing a higher sensitivity of the San Diego-based liquid biopsy provider's Target Selector, including its Switch-Blocker technology, which tests for rare cancers...

on 10/09/2019

2 min read